GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

F45 Training Holdings Inc., a leading global fitness community known for innovative, high-energy group workouts, announced ...

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Industry leaders share their thoughts and concerns about the health care landscape and how it will affect their 2025.

Browse in-depth TOC on " Global Biotechnology industry Outlook " 10 - Tables 20 - Figures 70 - Pages . The Global Biotech ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...